Prosecution Insights
Last updated: April 19, 2026
Application No. 17/599,811

LONG-LASTING COSMETIC COMPOSITION

Non-Final OA §103
Filed
Sep 29, 2021
Examiner
MERCIER, MELISSA S
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Roquette Freres
OA Round
3 (Non-Final)
72%
Grant Probability
Favorable
3-4
OA Rounds
2y 9m
To Grant
79%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allow Rate
852 granted / 1181 resolved
+12.1% vs TC avg
Moderate +7% lift
Without
With
+6.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
50 currently pending
Career history
1231
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
41.2%
+1.2% vs TC avg
§102
17.1%
-22.9% vs TC avg
§112
25.3%
-14.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1181 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on December 22, 2025 has been entered. Status of Application Receipt of Applicant’s remarks and amended claims filed on December 22, 2025 is acknowledged. Claims 20-29, 31-39, and 42 are pending in this application. Claims 20, 29, 31, and 33 have been amended. Claims 1-19, 30, and 40-41 have been cancelled. Claims 34-38 remain withdrawn from consideration as drawn to non-elected Groups II and III. Claims 20-29, 31-33, 39, and 42 are under examination in this application. Newly Applied Rejections Claim Objections Claim 39 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 22. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 20-29, 32-33, and 39 are rejected under 35 U.S.C. 103 as being unpatentable over Gombart et al. (KR 2015/0031238) in view of Parissaux et al. (WO 2014155015). Gombert discloses a cosmetic composition comprising at least one polymer which can include starch, at least one polyol, and an elastic mixture of water. The mixture imparts a resilience to the cosmetic product applied to the surface of the skin that naturally undergoes such changes as changes in facial expression, pressure of the fingers by contact, or contact of the clothes (abstract). Example 3 discloses the use of xanthan gum, starch, and glycerol (a polyol). The starch can be a starch hydrolysate, corn starch, pea starch, tapioca starch, potato starch, and wheat starch (claim 2). Regarding claim 23, as noted above, the starch can be pea starch. Regarding claim 24, as noted above, the starch can be a hydrolysate starch. Regarding claim 25, the starch is present in the amount of 10-30% by weight of the mixture (claim 1). Regarding claim 26, as noted above, glycerol is disclosed in Example 3. Additional polyols include sorbitol and glycol (claim 4). Regarding claim 27, the polyol is present in the amount of 20-60% by weight of the mixture (claim 1). Regarding claim 28, the components of Example 3 equal 42.66%. The example discloses the composition is then qs to 100 with purified water. Therefore, the water would be present in the amount of 57.34%. Regarding claim 29, as noted above, Example 3 utilizes xanthan gum. Regarding claim 32, Example 4 discloses ethanol. Regarding claim 33, the composition additionally comprises pigments. Gombert does not disclose the amylose percentage of the starch. Parissaux discloses a film forming composition comprising a hydroxypropyl starch and sorbitol (abstract). When the starch is a pea starch, the amylose content is between 25 and 45%. Regarding claim 21, a viscosity measured at 25 ° C. of less than or equal to 500 mPa.s. Regarding claims 22 and 39, as noted above, the amylose content is between 25 and 45%. It would have been obvious to one of ordinary skill in the art prior to the effective filing date of the invention to have to use the high amylose starch disclosed by Parissaux as the starch of Gombert since it is disclosed to be an ideal film forming polymer to make an elastic and cohesive film. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA S MERCIER whose telephone number is (571)272-9039. The examiner can normally be reached M-F 6:30 am to 4 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MELISSA S MERCIER/ Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Sep 29, 2021
Application Filed
Jan 30, 2025
Non-Final Rejection — §103
May 02, 2025
Response Filed
Jul 17, 2025
Final Rejection — §103
Oct 20, 2025
Applicant Interview (Telephonic)
Oct 20, 2025
Examiner Interview Summary
Dec 22, 2025
Request for Continued Examination
Dec 30, 2025
Response after Non-Final Action
Jan 27, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599556
OPHTHALMIC COMPOSITIONS
2y 5m to grant Granted Apr 14, 2026
Patent 12599706
ADHESION PREVENTION WITH SHEAR-THINNING POLYMERIC HYDROGELS
2y 5m to grant Granted Apr 14, 2026
Patent 12599576
TREATMENT OF POOR METABOLIZERS OF DEXTROMETHORPHAN WITH A COMBINATION OF BUPROPION AND DEXTROMETHORPHAN
2y 5m to grant Granted Apr 14, 2026
Patent 12576064
UROLITHIN GUMMY (PECTIN) FORMULATIONS
2y 5m to grant Granted Mar 17, 2026
Patent 12569454
NUCLEOPHILIC CHEMICALS USEFUL IN THE TREATMENT OF CISPLATIN-INDUCED SENSORY NEUROPATHY AND OTOTOXICITY
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
72%
Grant Probability
79%
With Interview (+6.9%)
2y 9m
Median Time to Grant
High
PTA Risk
Based on 1181 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month